EGFR and non-small cell lung carcinoma: Based on the results of the FLAURA trial, the third-generation EGFR–tyrosine kinase inhibitor (EGFR-TKI) osimertinib has become the global standard of care for the first-line treatment of advanced EGFR-mutant non-small cell lung cancer (NSCLC), demonstrating significant improvements in both progression-free and overall survival compared to earlier-generation TKIs (2).